Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNPAT | O15228 | 1/20 | 0.55 |
| ▸ | MMP1 | P03956 | 6/20 | 0.51 |
| ▸ | MMP3 | P08254 | 4/20 | 0.51 |
| ▸ | MMP9 | P14780 | 2/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.45 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.45 |
| ▸ | GHSR | Q92847 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15948101 | 0.96 | GNPAT (0.54) | GNPATMMP1MMP3MMP9OPRK1 | |
| SCHEMBL22695740 | 0.96 | GNPAT (0.54) | GNPATMMP1MMP3MMP9OPRK1 | |
| SCHEMBL14553984 | 0.92 | GNPAT (0.48) | GNPATMMP1MMP3MMP9CTSL | |
| SCHEMBL20072307 | 0.90 | GNPAT (0.52) | GNPATMMP1CTSLNPFFR1NPFFR2 | |
| SCHEMBL18499711 | 0.89 | GHSR (0.55) | GNPATCTSLGHSR | |
| SCHEMBL22845647 | 0.89 | GHSR (0.55) | GNPATCTSLGHSR | |
| SCHEMBL23128369 | 0.88 | MME (0.53) | GNPATMMP1MMP3HDAC3HDAC4 | |
| SCHEMBL30917923 | 0.87 | GNPAT (0.61) | GNPATMMP2 | |
| SCHEMBL15145509 | 0.86 | MME (0.53) | GNPATMMP1MMP3MMP9CTSL | |
| SCHEMBL27267618 | 0.86 | MME (0.53) | GNPATMMP1MMP3MMP9CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170218085-A1 | SITE-SPECIFIC LABELING METHODS AND MOLECULES PRODUCED THEREBY | NOVARTIS AG (CH) | 2017-08-03 | — | — | US | disclosed |
| US-9585970-B2 | Site-specific labeling methods and molecules produced thereby | NOVARTIS AG (CH) | 2017-03-07 | — | — | US | disclosed |
| US-20160311853-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2016-10-27 | — | — | US | disclosed |
| US-20150104468-A1 | SITE-SPECIFIC LABELING METHODS AND MOLECULES PRODUCED THEREBY | IRM LLC (BM) | 2015-04-16 | — | — | US | disclosed |
| US-20140065171-A1 | Site-Specific Labeling Methods and Molecules Produced Thereby | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2014-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150104468-A1 | SITE-SPECIFIC LABELING METHODS AND MOLECULES PRODUCED THEREBY | PTMS, DNPEP, PSAT1 | GNPAT 59/4885MMP1 4065/4885MMP3 3795/4885 |
| US-20160311853-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | CD47, NGLY1, VIP | GNPAT 3147/4885MMP1 1985/4885MMP3 2516/4885 |
| US-20140065171-A1 | Site-Specific Labeling Methods and Molecules Produced Thereby | PTMS, DNPEP, PSAT1 | GNPAT 36/4885MMP1 3914/4885MMP3 3597/4885 |
| US-20170218085-A1 | SITE-SPECIFIC LABELING METHODS AND MOLECULES PRODUCED THEREBY | PTMS, DNPEP, PSAT1 | GNPAT 36/4885MMP1 3914/4885MMP3 3597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.